Genmab to submit cancer candidate epcoritamab to the FDA before year-end
![Photo: Tuala Hjarnø / Genmab / PR](https://photos.watchmedier.dk/watchmedier/resize:fill:3840:0:0/plain/https://photos.watchmedier.dk/Images/article14130964.ece/ALTERNATES/schema-16_9/doc7ldfzv7v96u1jpoh21nf.jpg)
During the second half of 2022, Genmab and partner Abbvie will submit an application for marketing authorization from the FDA concerning their candidate epcoritamab. The target indication is relapsed/refractory large B-cell lymphoma (LBCL).
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
Get full access for you and your coworkers
Start a free company trial todayRelated articles
Analyst: Genmab cancer data is promising compared to rival
For subscribers
Genmab presents full data set for cancer drug
For subscribers
Genmab to buy back 370,000 shares
For subscribers